Vaccinex Announces Publication of VX15/2503 Non-clinical Toxicology Studies

ROCHESTER, N.Y., May 11, 2015 – Vaccinex Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, today announced publication of a manuscript entitled “Nonclinical Safety Evaluation of VX15/2503; a Humanized IgG4 Anti-SEMA4D Antibody” in Molecular Cancer Therapeutics.*

VX15/2503 is a first in class, monoclonal antibody discovered, characterized, and tested successfully by Vaccinex in preclinical models of cancer and neurological diseases. In preparation for human clinical trials, Vaccinex conducted preclinical toxicology studies that included pharmacokinetic and pharmacodynamic assessments. Single and repeat dose toxicology studies in rats or primates produced no clinical or anatomic findings of any significance at the highest dose tested, 100 mg/kg for rats and primates in the single dose and one-month studies, and 200 mg/kg for rats and primates in the six-month chronic dose studies. The findings published in this manuscript were used to support now-completed Phase 1 studies of VX15/2503 in oncology (NCT01313065) and multiple sclerosis (NCT01764737).

* Link to the article – http://mct.aacrjournals.org/content/early/2015/02/04/1535-7163.MCT-14-0924.full.pdf

About Vaccinex, Inc.
Vaccinex, Inc. is a privately held clinical-stage immunotherapy company engaged in the discovery and development of human therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, including multiple sclerosis and Huntington’s Disease. Vaccinex utilizes its proprietary ActivMAb® Antibody Discovery Technology for rapid, mammalian cell-based antibody selection to build its antibody pipeline and in service to its biopharmaceutical partners. Compared to other selection technologies, ActivMAb® combines the advantages of rapid and sensitive selection by virus panning and cell sorting in one technology, with intrinsic selection of antibodies that are efficiently expressed and stable in mammalian cells. Vaccinex is based in Rochester, New York. For more information and to contact Vaccinex, visit www.vaccinex.com.